Apollomics (APLM) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
OS Therapies (OSTX) has outperformed Apollomics (APLM) over the past year, losing 28.6% versus a loss of 42.4%. OS Therapies is the larger company by market cap ($61.8 million vs $61.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | OSTX |
|---|---|---|
| Share price | $21.10 | $1.32 |
| Market cap | $61.51M | $61.78M |
| 1-day change | -0.00% | -6.38% |
| YTD return | +12.86% | -5.71% |
| 1-year return | -42.43% | -28.65% |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $-7.57 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-53.86M | $-28.75M |
| 52-week high | $36.53 | $2.25 |
| 52-week low | $10.01 | $1.15 |
| Distance from 52-week high | -42.23% | -41.33% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +543.94% |
| Average volume | 15.35K | 578.15K |
| Shares outstanding | 2.91M | 46.81M |
| Employees | 14 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed APLM by 13.8 percentage points over the past year.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
APLM vs OSTX FAQ
Which is bigger, Apollomics or OS Therapies?
OS Therapies (OSTX) is larger, with a market capitalization of $61.78M compared with $61.51M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or OSTX?
OSTX returned -28.65% over the past 12 months, compared with -42.43% for APLM (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.